Non-Small Cell Cancer | What I Tell My Patients: Integrating New Research Information into Current Clinical Care — Non-Small Cell Lung Cancer with an EGFR Mutation

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics:

• Introduction (0:00)
• The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02)
• The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58)
• Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38)
• Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45)
• Common Toxicities Associated with Amivantamab (45:07)
• The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06)
• Tolerability and Other Practical Considerations with HER3-DXd (1:01:06)
• Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26)

NCPD information and select publications